Kanilad (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilizes neuronal membranes and reduces hyper‑excitability. It also binds to CRMP‑2, influencing neuronal differentiation and axonal growth, contributing to its seizure‑controlling properties.

The specific dose of Kanilad is individualized. A qualified prescriber determines the appropriate starting dose and titration schedule based on the patient’s clinical condition, age, renal and hepatic function, and response to therapy.

Lacosamide’s pregnancy category is listed as unknown. Use during pregnancy or lactation only if the potential therapeutic benefit justifies any potential risk to the fetus or infant. Clinicians should discuss risks and benefits with the patient.

To request Kanilad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older sodium‑channel blockers such as carbamazepine, Lacosamide offers a distinct mechanism by enhancing slow inactivation rather than fast inactivation. This can result in a different side‑effect profile and may be better tolerated in patients who experience adverse effects with traditional agents.

Kanilad should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct light, and ensure the packaging remains tightly closed until use.

Kanilad is taken orally, usually with or without food, as directed by the prescribing physician. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, suicidal thoughts or behaviors, severe skin reactions like Stevens‑Johnson syndrome, hypersensitivity reactions including anaphylaxis, and significant liver enzyme elevations. Patients should be monitored for these events.

Kanilad is contraindicated in patients with known hypersensitivity to Lacosamide or any of its excipients. Caution is advised for individuals with pre‑existing cardiac conduction disorders, severe hepatic impairment, or those taking medications that may cause dangerous interactions.